Mosmass (Alendronate Sodium Trihydrate)

Alendronate sodium, the active ingredient in Mosmass, is a bisphosphonate presented as an oral tablet for oral use. It treats osteoporosis and related bone disorders in adult patients, helping to reduce fracture risk by inhibiting bone resorption. By binding to bone mineral surfaces, it selectively targets osteoclast activity, leading to decreased bone turnover.

GNH USA supplies Mosmass as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards.

Mosmass (alendronate sodium) is indicated for conditions involving increased bone turnover within the skeletal system.

- Osteoporosis: reduces risk of vertebral and hip fractures by inhibiting bone resorption. - Paget's disease of bone: normalizes abnormal bone remodeling and alleviates bone pain. - Glucocorticoid‑induced osteoporosis: prevents bone loss associated with long‑term corticosteroid therapy.

Alendronate sodium may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Upper gastrointestinal irritation: dyspepsia, abdominal pain, or nausea. - Esophageal discomfort: heartburn or reflux symptoms. - Musculoskeletal pain: transient bone, joint, or muscle aches. - Headache: mild to moderate intensity. - Flu‑like symptoms: transient fever or chills.

Serious or Rare Side Effects: - Osteonecrosis of the jaw: exposed bone in the oral cavity. - Atypical femoral fractures: low‑energy fractures of the subtrochanteric region. - Severe esophageal ulceration or perforation. - Acute renal impairment: sudden decrease in kidney function. - Hypocalcemia: low blood calcium levels requiring monitoring.

When prescribing Mosmass, clinicians should consider several precautionary measures to ensure safe use.

- Assess renal function: avoid use in patients with severe renal impairment. - Verify calcium and vitamin D status: correct deficiencies before initiating therapy. - Review gastrointestinal history: contraindicated in patients with esophageal disorders. - Advise upright posture: take the tablet with a full glass of water and remain upright for at least 30 minutes. - Monitor for atypical fractures: evaluate persistent thigh or groin pain. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Alendronate sodium can interact with other medicines, affecting its absorption or increasing toxicity.

Major Interactions (Avoid): - Calcium supplements or antacids containing calcium, magnesium, aluminum, or iron: markedly reduce alendronate absorption. - Concomitant use of other bisphosphonates: increased risk of cumulative bone toxicity. - Systemic corticosteroids: may exacerbate risk of osteonecrosis of the jaw.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may alter gastric pH and affect drug bioavailability. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of gastrointestinal irritation. - Diuretics (loop or thiazide): may predispose to hypocalcemia; monitor serum calcium levels.